JP7137563B2 - がん治療用の抗Ｓｉｇｌｅｃ－７抗体 - Google Patents

がん治療用の抗Ｓｉｇｌｅｃ－７抗体 Download PDF

Info

Publication number
JP7137563B2
JP7137563B2 JP2019527783A JP2019527783A JP7137563B2 JP 7137563 B2 JP7137563 B2 JP 7137563B2 JP 2019527783 A JP2019527783 A JP 2019527783A JP 2019527783 A JP2019527783 A JP 2019527783A JP 7137563 B2 JP7137563 B2 JP 7137563B2
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
siglec
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019527783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526622A (ja
JP2019526622A5 (enExample
Inventor
ベビントン クリストファー
コーバー ウター
トマセビク ネナド
エル バデル スージー
ラーセン ケネス
Original Assignee
アラコス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス，インコーポレイティド filed Critical アラコス，インコーポレイティド
Publication of JP2019526622A publication Critical patent/JP2019526622A/ja
Publication of JP2019526622A5 publication Critical patent/JP2019526622A5/ja
Application granted granted Critical
Publication of JP7137563B2 publication Critical patent/JP7137563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019527783A 2016-08-05 2017-08-04 がん治療用の抗Ｓｉｇｌｅｃ－７抗体 Active JP7137563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
US62/371,680 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2019526622A JP2019526622A (ja) 2019-09-19
JP2019526622A5 JP2019526622A5 (enExample) 2020-09-17
JP7137563B2 true JP7137563B2 (ja) 2022-09-14

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527783A Active JP7137563B2 (ja) 2016-08-05 2017-08-04 がん治療用の抗Ｓｉｇｌｅｃ－７抗体

Country Status (13)

Country Link
US (1) US11773162B2 (enExample)
EP (1) EP3494142A4 (enExample)
JP (1) JP7137563B2 (enExample)
KR (1) KR20190035863A (enExample)
CN (1) CN109790223A (enExample)
AU (1) AU2017307616A1 (enExample)
BR (1) BR112019002331A2 (enExample)
CA (1) CA3032437A1 (enExample)
EA (1) EA201990296A1 (enExample)
IL (1) IL264674B2 (enExample)
MX (1) MX2019001471A (enExample)
SG (1) SG11201901020RA (enExample)
WO (1) WO2018027203A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11773162B2 (en) 2016-08-05 2023-10-03 Allakos, Inc. Anti-Siglec-7 antibodies for the treatment of cancer
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP2020527144A (ja) 2017-07-10 2020-09-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
EP3737410A4 (en) * 2018-01-11 2022-04-20 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20230210989A1 (en) * 2020-06-03 2023-07-06 Kar Muthumani Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
AU2023393653A1 (en) 2022-12-14 2025-05-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
WO2007120815A2 (en) * 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
CA2691734A1 (en) * 2007-07-04 2009-01-08 Forerunner Pharma Research Co., Ltd. Anti-muc17 antibody
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US20160115231A1 (en) * 2013-05-21 2016-04-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
JP6125110B2 (ja) 2014-08-07 2017-05-10 第一三共株式会社 抗Ｏｒａｉ１抗体
JP7525980B2 (ja) * 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
EP3402516A4 (en) * 2016-01-12 2020-01-08 Palleon Pharmaceuticals Inc. USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
CN108699158B (zh) 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
US11773162B2 (en) 2016-08-05 2023-10-03 Allakos, Inc. Anti-Siglec-7 antibodies for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Also Published As

Publication number Publication date
CA3032437A1 (en) 2018-02-08
JP2019526622A (ja) 2019-09-19
CN109790223A (zh) 2019-05-21
IL264674B2 (en) 2023-09-01
BR112019002331A2 (pt) 2019-06-18
IL264674B1 (en) 2023-05-01
AU2017307616A1 (en) 2019-02-28
US20190194323A1 (en) 2019-06-27
EP3494142A1 (en) 2019-06-12
SG11201901020RA (en) 2019-03-28
US11773162B2 (en) 2023-10-03
EP3494142A4 (en) 2020-04-01
EA201990296A1 (ru) 2019-08-30
MX2019001471A (es) 2019-10-30
IL264674A (enExample) 2019-03-31
WO2018027203A1 (en) 2018-02-08
KR20190035863A (ko) 2019-04-03

Similar Documents

Publication Publication Date Title
JP7137563B2 (ja) がん治療用の抗Ｓｉｇｌｅｃ－７抗体
US20190315870A1 (en) Antibodies against mica and/or micb and uses thereof
CA3054824A1 (en) Anti-icos agonist antibodies and uses thereof
US20180134771A1 (en) Novel immunomodulatory therapeutic strategies targeting tumors in cancer
EP3955960A1 (en) Ipilimumab variants with enhanced specificity for binding at low ph
JP7505148B2 (ja) Ｌａｇ３に結合する抗体およびその使用
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
JP7342005B2 (ja) エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体
AU2021308586A1 (en) Therapeutic antibodies and their uses
US20250042996A1 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
JP2025537137A (ja) 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
TW202523694A (zh) 抗muc16抗體及其用途
TW202446419A (zh) 使用抗ｏｘ４０抗體與抗ｐｄ１抗體之組合的癌症治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220810

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220902

R150 Certificate of patent or registration of utility model

Ref document number: 7137563

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150